RxDoctor Payments Data

Oleg Lushpenko, MD

Family Medicine · Brooklyn, NYNPI 1184662181

Payments from drug & device makers

$6,469in general payments, 2019–2025

Across 74 payments — averaging $87.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$359
  • Novo Nordisk$338
  • Kowa Pharmaceuticals America, Inc.$229
  • Amarin Pharma, Inc.$147
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$40%
  • Food & beverage$6,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,469 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$36,339
Medicare patients
51
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JentaduetoLinagliptin/Metformin Hcl21$18,370
LinzessLinaclotide16$8,483
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,335
Albuterol Sulfate HfaAlbuterol Sulfate70$2,567
Potassium Chloride35$2,556
Dexlansoprazole DrDexlansoprazole15$2,218
Diclofenac Sodium51$1,612
Mometasone Furoate64$1,589
Atorvastatin Calcium156$1,280
Ramelteon13$1,237
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide72$966
Clobetasol Propionate23$953
Glipizide-MetforminGlipizide/Metformin Hcl32$947
Omeprazole86$678
Amlodipine Besylate160$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJentadueto$359$18,37021 claims
AbbVieLinzess$2,177$8,48316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →